TP53 and cancer: Interestingly, in numerous mouse models of Myc-driven tumors, tumor deterioration via Myc repression is hindered by simultaneous suppression of the TP53 protein, highlighting the relevance of an intact p53 pathway for treating cancer by targeting Myc18–20.